FIGURE 11.
PPARγ antagonist T0070907 (50 nm) blocks pioglitazone actions on TNFα, SOCS3, and IRTyr-1150/1151. All work was done in REC and Müller cells left untreated (NT), treated with pioglitazone (PIO), treated with T0070907 only, or treated with pioglitazone + T0070907. A–D, REC results; E–H, Müller cell results. A and E show that T0070907 inhibited pioglitazone actions using the PPARγ activity assay. B and F demonstrate that T00709707 antagonized pioglitazone actions on TNFα, whereas C and G show T0070907 actions on SOCS3. D and H show that pioglitazone's ability to increase IRTyr-1150/1151 requires PPARγ because it was blocked by T0070907. *, p < 0.05 versus normal glucose (NG) untreated; #, p < 0.05 versus high glucose untreated; $, p < 0.05 versus high glucose (HG) + pioglitazone. Data are mean ± S.E.; n = 4 for all treatments. A.U., arbitrary units.